Dr. Kimberly Struble is currently a Medical Team Leader in the Division of Antivirals at the Food and Drug Administration. She received a baccalaureate of Science in Pharmacy from the University of Connecticut and a Doctor of Pharmacy from the University of Arkansas for Medical Sciences.
She joined FDA in October 1993 and served in various positions as a project manager and clinical reviewer. She left FDA in March 2002 to a pharmaceutical company and rejoined FDA in May 2003. During her career, she has been involved in all phases of clinical drug development and leads a team responsible for the development of new products for the treatment and prevention of HIV infection, hepatitis B and C, influenza, various herpes infections, COVID-19 and other emerging viral infections. She is a member of the Department of Health and Human Services HIV Treatment Guidelines Panel. She serves on various committees including the Forum for Collaborative Research, Long Acting/ Extended Release Antiretroviral Research Resource Program and is the FDA representative to CDC for occupational post-exposure prophylaxis public health service working group. She has over 35 publications and 100 presentations relating to antiviral development and FDA regulations.
